68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
REDONDO M, BUNDY B, PARIKH H, YOU L, TRIOLO T, FERRAT L, TEMPLEMAN E, TOSUR M, STECK A, GOTTLIEB P, ONENGUT-GUMUSCU S, RICH S, ORAM R, HEROLD K, KRISCHER J. 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention. Diabetes 2024, 73 DOI: 10.2337/db24-68-or.Peer-Reviewed Original ResearchT1D riskAssociated with higher risk of progressionMarkers of response to treatmentNon-HLA single nucleotide polymorphismsEvaluate risk-benefit ratiosHigh risk of progressionGenetic risk scoreSingle nucleotide polymorphismsCox modelType 1 diabetes genetic risk scoreResponse to immunotherapyRisk of progressionIncreased T1D riskAssociated with higher riskResponse to treatmentRisk-benefit ratioInteraction termsT1D preventionType 1 diabetes preventionPrevent T1DTreatment armsHazard ratioScore 2Treated armClinical trialsComparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals
Sims E, Cuthbertson D, Jacobsen L, Ismail H, Nathan B, Herold K, Redondo M, Sosenko J. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. The Journal Of Clinical Endocrinology & Metabolism 2024, 109: 2116-2123. PMID: 38267821, PMCID: PMC11244203, DOI: 10.1210/clinem/dgae048.Peer-Reviewed Original ResearchSix-month changesPrevention trialsC-peptidePredicting diabetesMetabolic endpointsPreventive treatment effectsMetabolic measuresEffect of disease-modifying therapiesProportional hazards regressionTreatment effectsResponse to immunotherapyMeasurement of glucoseNatural history studiesPrevention StudyHazards regressionInclusion criteriaDisease-modifying therapiesT1D prevention trialsComparing placeboTreatment armsTeplizumabTrialNet PathwayHigh riskDetect treatment effectsCombined glucose